AstraZeneca Ad Minimizes Risks Posed By Highest Crestor Dose, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca's newspaper ads defending the safety of Crestor minimized the risks associated with the 40 mg dose of the statin, FDA says in a Dec. 21 "untitled" letter to the company
You may also be interested in...
Crestor Campaign Makes FDA Complain; "Clearly The Best" Given A Rest
An FDA "untitled" letter takes issue with AstraZeneca's presentation of comparative claims to other statins in an ad campaign that states Crestor is "clearly the best." This is the second ad division letter sent to AstraZeneca for Crestor promotions. AstraZeneca says the FDA-cited campaign concluded at the end of 2004.
Crestor Campaign Makes FDA Complain; "Clearly The Best" Given A Rest
An FDA "untitled" letter takes issue with AstraZeneca's presentation of comparative claims to other statins in an ad campaign that states Crestor is "clearly the best." This is the second ad division letter sent to AstraZeneca for Crestor promotions. AstraZeneca says the FDA-cited campaign concluded at the end of 2004.
Crestor Safety Defense Misrepresents FDA Position, Agency Tells Company
An AstraZeneca “patient safety” print ad that ran in mid-November “misleadingly suggests that the agency does not believe that Crestor poses safety concerns,” the FDA ad division says in an “untitled” letter to the company. The Crestor ad asserted FDA has concluded safety concerns about rosuvastatin “have no medical or scientific basis.”